Cannabis Report
Home > Boards > US Listed > Cannabis >

Zynerba Pharmaceuticals (ZYNE)

ZYNE RSS Feed
Add ZYNE Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 7/15/2018 6:50:15 PM - Followers: 66 - Board type: Free - Posts Today: 0


Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.

Investor Relations

Corporate Profile

Zynerba (NASDAQ: ZYNE) is pioneering the development of patent-protected, next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its two lead product candidates in development include ZYN002 and ZYN001, which are being evaluated in five indications. ZYN002 is the first and only synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In June 2016, the company initiated the STAR 1 Phase 2 clinical trial in refractory epilepsy patients and in August 2016, initiated the STOP Phase 2 clinical trial in patients with osteoarthritis of the knee. A Phase 2 clinical trial in patients with Fragile X syndrome will be initiated in the second half of 2016. 

ZYN001, a prodrug of THC that enables transdermal delivery through the skin and circulatory system via a patch, is in preclinical development. A Phase 1 clinical trial is planned in the first half of 2017.

In August 2015, Zynerba completed an initial public offering, raising net proceeds of $42.1 million. As of June 30, 2016, cash and cash equivalents totaled $32.1 million, which is projected to fund five Phase 2 clinical trials through 2017.





Zynerba Pharmaceuticals, Inc., (Nasdaq: ZYNE) announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common stock at the public offering price, less the underwriting discount. Zynerba's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the symbol "ZYNE" on August 5, 2015.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, and Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. This offering is being made only by means of a prospectus.



Extremely low float:

Fundamentals

A table providing the fundamentals of the stock
EPS (TTM) 9/30/2016 | -2.47
P/E Ratio 9/30/2016 | --
Market Cap Micro Cap | 146M
Shares Outstanding 9.95M
Float 7.2M

 

Cannabis Report
ZYNE
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ZYNE News: Current Report Filing (8-k) 07/19/2018 04:07:00 PM
ZYNE News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 07/19/2018 04:04:22 PM
ZYNE News: Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock 07/19/2018 04:01:00 PM
ZYNE News: Current Report Filing (8-k) 07/12/2018 08:24:50 AM
ZYNE News: Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome 07/12/2018 07:30:00 AM
News News Alert: Current Report Filing (8-k) 07/19/2018 04:07:00 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#1066   Winnnnnning WolfOfGrnStreet 07/15/18 06:50:15 PM
#1065   Yes maybe more.IF you go long.another's that have mojo joyo 07/05/18 05:55:48 PM
#1064   Not this morning Oh my Down to $7 mjw007 07/05/18 08:55:24 AM
#1063   $20+ Target VERITAS77 06/15/18 07:23:30 AM
#1062   Possibly. But by that logic all the companies MoToM 05/11/18 12:30:35 PM
#1061   What a disaster. I now agree synthetics suck surfgreen 05/09/18 06:04:30 PM
#1060   Ye ye WolfOfGrnStreet 05/08/18 09:40:51 PM
#1059   65 Million Cash on Hand???? Cannabis 2013 04/27/18 09:55:10 PM
#1058   Zynerba Pharmaceuticals Announces Oral Presentation of ZYN002 Data Cbdpotential 04/23/18 08:45:59 AM
#1057   MJs https://www.washingtonpost.com/politics/trump-gardner-strike-deal-on-legaliz bobbodom 04/13/18 01:49:33 PM
#1056   ZYNE. LETS GET IT BABY WolfOfGrnStreet 04/12/18 09:23:14 PM
#1055   Zynerba Initiates Open-Label Phase 2 Trial of ZYN002 jcamp212 04/10/18 03:14:57 PM
#1054   Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of Cbdpotential 04/10/18 09:32:08 AM
#1053   Nice movement today! (for a change) Pisstested 04/03/18 01:40:31 PM
#1052   https://technical420.com/cannabis-article/zynerba-pharmaceuticals-announces-publ greenwillow 03/26/18 09:22:26 AM
#1051   Zynerba Plans Study of CBD-Based ZYN002 for Fragile jcamp212 03/05/18 11:29:17 AM
#1050   What a mess this stock turned out to surfgreen 02/28/18 03:02:19 PM
#1049   Well I sure could use some good news Pisstested 02/27/18 02:28:39 PM
#1048   Why? Technicals? I don’t see any catalysts until surfgreen 02/20/18 01:26:38 PM
#1047   Looking for a big bounce here. MD-420 02/14/18 07:59:02 AM
#1046   Not looking good today. Triminator88 02/02/18 10:34:27 AM
#1045   Woot woot!! That’s 5 higher then the highest surfgreen 01/29/18 03:59:19 PM
#1044   ANALYST ACTIONS: LADENBURG THALMANN INITIATES ZYNERBA PHARMACEUTICALS WITH a surfer 01/29/18 03:13:13 PM
#1042   Well, just put in my last sell order WolfOfGrnStreet 01/26/18 11:43:37 AM
#1041   It would sure help to hear something. a surfer 01/25/18 02:44:35 PM
#1040   Unreal manipulation for a big board stock. Need surfgreen 01/25/18 10:07:36 AM
#1039   Afternoon rally. a surfer 01/24/18 10:00:04 PM
#1038   Agreed jjh573 01/24/18 12:13:12 PM
#1037   Broken POS surfgreen 01/24/18 11:08:47 AM
#1036   $ZYNE grabbed some calls here, chart still is jjh573 01/22/18 10:58:22 AM
#1035   I excited at 12.5. May get back in MD-420 01/19/18 05:37:05 AM
#1034   This is looking like solid entry point adding KingTigerII 01/17/18 09:40:17 AM
#1033   I sold. Have a 100 shares left. I’ll WolfOfGrnStreet 01/16/18 09:58:08 PM
#1032   Golden cross forming yet this turd keeps drifting surfgreen 01/16/18 01:03:55 PM
#1031   Need to bounce here to hold the uptrend. surfgreen 01/09/18 03:09:56 PM
#1030   I believe gw is doing the same. And MD-420 01/08/18 07:35:13 AM
#1029   I hear ya, I just feel synthetic is djmurdock 01/07/18 02:17:48 AM
#1028   In all fairness sometimes quitting and re-focusing is surfgreen 01/06/18 09:02:02 PM
#1027   As most know I was a huge fan djmurdock 01/05/18 01:52:26 PM
#1024   You could be right. So many companies jumping MD-420 12/28/17 08:19:18 AM
#1023   They need to make this s+** as steady WolfOfGrnStreet 12/28/17 12:36:21 AM
#1022   Have lots of XRP! Great choice! As always Bescaredxx 12/22/17 10:05:18 AM
#1021   Don’t be dumb. Invest in this and ripple WolfOfGrnStreet 12/21/17 10:58:03 PM
#1020   Think of the midget queen as a metaphor MD-420 12/21/17 10:22:55 AM
#1019   Now that i gotta see! Lmao Bescaredxx 12/21/17 09:45:44 AM
#1018   I think it will turn out to be MD-420 12/21/17 09:33:28 AM
#1017   Isnt that normally the case! Lol they want Bescaredxx 12/21/17 07:45:35 AM
#1016   This double camel toe is really playing hard MD-420 12/21/17 07:34:25 AM
#1015   LMAO! Sweet! a surfer 12/18/17 10:09:08 AM
#1014   Full double camel toe forming! News of zyn001 Bescaredxx 12/18/17 12:50:06 AM
PostSubject